These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

525 related articles for article (PubMed ID: 1735618)

  • 1. Combination therapy with thymosin alpha 1 potentiates the anti-tumor activity of interleukin-2 with cyclophosphamide in the treatment of the Lewis lung carcinoma in mice.
    Mastino A; Favalli C; Grelli S; Rasi G; Pica F; Goldstein AL; Garaci E
    Int J Cancer; 1992 Feb; 50(3):493-9. PubMed ID: 1735618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination treatment using thymosin alpha 1 and interferon after cyclophosphamide is able to cure Lewis lung carcinoma in mice.
    Garaci E; Mastino A; Pica F; Favalli C
    Cancer Immunol Immunother; 1990; 32(3):154-60. PubMed ID: 2126987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor effect of thymosin alpha 1/interleukin-2 or thymosin alpha 1/interferon alpha,beta following cyclophosphamide in mice injected with highly metastatic Friend erythroleukemia cells.
    Garaci E; Pica F; Mastino A; Palamara AT; Belardelli F; Favalli C
    J Immunother Emphasis Tumor Immunol; 1993 Jan; 13(1):7-17. PubMed ID: 8435433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thymosin alpha 1 potentiates interleukin 2-induced cytotoxic activity in mice.
    Mastino A; Favalli C; Grelli S; Innocenti F; Garaci E
    Cell Immunol; 1991 Mar; 133(1):196-205. PubMed ID: 1991327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemo-immunotherapy for murine B16 melanoma.
    Pica F; Fraschetti M; Matteucci C; Tuthill C; Rasi G
    Anticancer Res; 1998; 18(5A):3571-8. PubMed ID: 9858941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats.
    Rasi G; Silecchia G; Sinibaldi-Vallebona P; Spaziani E; Pierimarchi P; Sivilia M; Tremiterra S; Garaci E
    Int J Cancer; 1994 Jun; 57(5):701-5. PubMed ID: 8194879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
    Gold JE; Zachary DT; Osband ME
    Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive transfer of anti-CD3-activated CD4+ T cells plus cyclophosphamide and liposome-encapsulated interleukin-2 cure murine MC-38 and 3LL tumors and establish tumor-specific immunity.
    Saxton ML; Longo DL; Wetzel HE; Tribble H; Alvord WG; Kwak LW; Leonard AS; Ullmann CD; Curti BD; Ochoa AC
    Blood; 1997 Apr; 89(7):2529-36. PubMed ID: 9116299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor and antimetastatic effects of dacarbazine combined with cyclophosphamide and interleukin-2 in Lewis lung carcinoma (3LL).
    Tentori L; Leonetti C; Lozupone F; Bonmassar E
    Cancer Immunol Immunother; 1995 Dec; 41(6):375-83. PubMed ID: 8635195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptively transferred ex vivo activated memory T cells with cyclophosphamide: effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
    Gold JE; Zachary DT; Osband ME
    Clin Immunol Immunopathol; 1994 Oct; 73(1):115-22. PubMed ID: 7923908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide.
    Hosokawa M; Sawamura Y; Morikage T; Okada F; Xu ZY; Morikawa K; Itoh K; Kobayashi H
    Cancer Immunol Immunother; 1988; 26(3):250-6. PubMed ID: 3260132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced immune response and antitumor immunity with combinations of biological response modifiers.
    Garaci E; Mastino A; Favalli C
    Bull N Y Acad Med; 1989 Jan; 65(1):111-9. PubMed ID: 2481523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced antitumor immune responses of IL-2 gene-modified tumor vaccine by combination with IL-1 and low dose cyclophosphamide.
    Cao X; Zhang W; Wan T; Yu Y; Tao Q; Wang J
    J Exp Clin Cancer Res; 1999 Jun; 18(2):173-9. PubMed ID: 10464704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Importance in timing of cyclophosphamide on the enhancement of interleukin-2-induced cytolysis.
    Katsanis E; Bausero MA; Ochoa AC; Loeffler CM; Blazar BR; Leonard AS; Anderson PM
    Cancer Immunol Immunother; 1991; 34(2):74-8. PubMed ID: 1760819
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.
    Naito K; Pellis NR; Kahan BD
    Cancer Res; 1988 Jan; 48(1):101-8. PubMed ID: 3257158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
    Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
    J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo resistance of secondary antitumor immune response to cyclophosphamide: effects on T cell subsets.
    Peppoloni S; Mathieson BJ; Herberman RB; Overton RW; Gorelik E
    Cancer Immunol Immunother; 1987; 24(1):49-56. PubMed ID: 2949833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemo-immunotherapy of murine solid tumors: enhanced therapeutic effects by interleukin-2 combined with interferon alpha and the role of specific T cells.
    Kedar E; Rutkowski Y; Leshem B
    Cancer Immunol Immunother; 1992; 35(1):63-8. PubMed ID: 1611625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy with natural interleukins and/or thymosin alpha 1 potently augments T-lymphocyte responses of hydrocortisone-treated aged mice.
    Hadden JW; Saha A; Sosa M; Hadden EM
    Int J Immunopharmacol; 1995 Oct; 17(10):821-8. PubMed ID: 8707447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunochemotherapy in B-16-melanoma-cell-transplanted mice with combinations of interleukin-2, cyclophosphamide, and PSK.
    Ueno Y; Kohgo Y; Sakamaki S; Itoh Y; Takahashi M; Hirayama Y; Niitsu Y
    Oncology; 1994; 51(3):296-302. PubMed ID: 8196915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.